Keywords: b-ms, file, nda, abilitat, 4th, quarter, bristol-myers
B-MS to file NDA for Abilitat in 4th quarter
Article | 27 April 2001
Bristol-Myers Squibb has said it intends to file for US Food and DrugAdministration approval of its experimental schizophrenia drug Abilitat ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
